Physician profile
Daniel T Huberman
NPI 1629231279
$3,995.58
in general payments reported to CMS, 2019-2025
47 companies · $1,175 in 2025
The $1,175 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $695 · 2020: $107 · 2021: $237 · 2022: $610 · 2023: $520 · 2024: $652 · 2025: $1,175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,205 · Education: $82.34 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,205.28 |
| Education | $82.34 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $436.96 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $413.51 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $303.95 | 2019-2025 | Evenity, Tepezza, Prolia |
| Amneal Pharmaceuticals LLC | $271.90 | 2019-2025 | Unithroid |
| Abbvie INC. | $187.34 | 2019-2025 | |
| Dexcom, INC. | $177.64 | 2021-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $168.35 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $166.05 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.27 | 2019-2025 | Jardiance |
| Mannkind Corporation | $117.12 | 2023-2025 | Afrezza |
| Astrazeneca Pharmaceuticals LP | $110.34 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $109.88 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Ibsa Pharma INC. | $97.95 | 2019-2025 | Tirosint, Licart, Flector |
| Pfizer INC. | $94.04 | 2019-2025 | |
| Ascendis Pharma Endocrinology INC | $89.42 | 2023-2025 | Yorvipath |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $78.27 | 2021-2025 | Strensiq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.89 | 2019-2023 | Cycloset |
| Medtronic, INC. | $68.56 | 2021-2025 | Minimed 780g |
| Insulet Corporation | $64.81 | 2023-2025 | Omnipod |
| Abbott Laboratories | $62.83 | 2024-2025 | Freestyle Libre |
| Ipsen Biopharmaceuticals, INC | $61.16 | 2021-2022 | |
| Medtronic Minimed, INC. | $57.94 | 2019 | |
| Valeritas, INC. | $53.29 | 2019 | |
| Currax Pharmaceuticals LLC | $45.77 | 2023-2024 | Contrave |
| Ultragenyx Pharmaceutical INC. | $43.12 | 2019-2021 | |
| Amarin Pharma, INC. | $43.05 | 2019-2020 | |
| Eisai INC. | $37.63 | 2019 | |
| Alvogen INC | $33.95 | 2025 | Teriparatide |
| Tandem Diabetes Care, INC. | $33.26 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Antares Pharma, INC. | $32.36 | 2019 | |
| Corcept Therapeutics | $32.30 | 2019-2025 | Korlym |
| Cequr Corporation | $28.03 | 2021-2025 | Cequr Simplicity |
| Radius Health, INC. | $27.68 | 2019-2020 | |
| Aytu Biopharma, INC. | $26.93 | 2019 | |
| Beta Bionics, INC. | $26.58 | 2023 | Ilet Bionic Pancreas |
| Azurity Pharmaceuticals, INC. | $18.57 | 2025 | Azmiro |
| Acella Pharmaceuticals, LLC | $17.76 | 2025 | NP Thyroid 60 |
| Sequel Med Tech, LLC | $17.71 | 2025 | Twiist |
| Glaxosmithkline, LLC. | $16.31 | 2025 | Shingrix, Arexvy |
| Averitas Pharma INC. | $16.23 | 2025 | Qutenza |
| Amryt Pharma Holdings LTD | $15.08 | 2023 | Mycapssa |
| Alfasigma USA, INC. | $14.75 | 2022 | |
| Clarus Therapeutics INC. | $14.60 | 2021 | |
| Verity Pharmaceuticals INC. | $14.00 | 2025 | Tlando |
| Tolmar, INC. | $13.94 | 2025 | Jatenzo |
| Merck Sharp & Dohme LLC | $13.02 | 2019 | |
| Shire North American Group INC | $12.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Huberman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.